Progress in the epigenetics of thyroid associated ophthalmopathy

doi:10.3877/cma.j.issn.2095-2007.2023.04.007

Abstract

Abstract:

The occurrence and development of thyroid associated ophthalmopathy (TAO) is related to the differential gene expression caused by DNA methylation, non coding RNA regulation, microRNA (miRNA). The miRNA-155 and miRNA-146a participated in the pathological process by participating in immune inflammation and the proliferation and differentiation of adipose tissue. The expression of miRNA-21 was correlated with the activity and severity of TAO. The miRNA-130a and miRNA-27 play an important role in the adipogenic differentiation of TAO orbital fibroblasts and the proliferation of adipose tissue. The miRNA-199a-3p and 5p increased tissue oxidative stress and angiogenesis in orbital adipocytes of TAO patients. The expression of miRNA-183 and miRNA-96 was increased in peripheral blood CD4⁺ T cells of TAO patients, which regulate immunity to participate in the progression. The miRNA-29 inhibits cell fibrosis by restricting transforming growth factor-β1 Signal path. The miRNA-143 regulates the inflammatory response by directly targeting insulin like growth factor-1 receptor and indirectly reducing thyrotropin receptor and nucleotide oligomerization domain-like receptor thermal protein domain associated protein 3 levels. In addition, the epigenetic regulation of long chain non coding RNAs, circular RNAs, transfer RNA derived fragments, and histone modification inactivation are also related to the pathogenesis of TAO.

Key words: Thyroid associated ophthalmopathy, Epigenetics, DNA Methylation, Non-coding RNA, Histone modification

Ruiqi Zhang, Lijuan Zhang, Bin Sun. Progress in the epigenetics of thyroid associated ophthalmopathy[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(04): 226-230.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2023.04.007

https://zhykyxzz.cma-cmc.com.cn/EN/Y2023/V13/I04/226

Figures/Tables 1

References 50

[1]	廖洪斐，余进海. 甲状腺相关性眼病治疗现状[J]. 中华眼科杂志，2022，58(8)：635－640.
[2]	Yin X, Latif R, Bahn R, et al. Genetic profiling in Graves′ disease: further evidence for lack of a distinct genetic contribution to Graves′ ophthalmopathy[J]. Thyroid, 2012, 22(7): 730－736.
[3]	Khong JJ, Wang LY, Smyth GK, et al. Differential gene expression profiling of orbital adipose tissue in thyroid orbitopathy[J]. Invest Ophthalmol Vis Sci, 2015, 56(11): 6438－6447.
[4]	Rotondo DG, Bucci I, Lanzolla G, et al. Genetic profiling of orbital fibroblasts from patients with Graves′ orbitopathy[J]. J Clin Endocrinol Metab, 2021, 106(5): e2176－e2190.
[5]	Zhu L, Li S, He S, et al. The critical role of m(6)A methylation in the pathogenesis of Graves′ ophthalmopathy[J]. Eye Vis (Lond), 2020, 7(1): 55.
[6]	Virakul S, Somparn P, Pisitkun T, et al. Integrative analysis of proteomics and DNA methylation in orbital fibroblasts from Graves′ ophthalmopathy[J]. Front Endocrinol, 2020, 11: 619989.
[7]	Xin Z, Hua L, Shi TT, et al. A genome－wide DNA methylation analysis in peripheral blood from patients identifies risk loci associated with Graves′ orbitopathy[J]. J Endocrinol Invest, 2018, 41(6): 719－727.
[8]	Kozlowski E, Wasserman GA, Morgan M, et al. The RNA uridyltransferase Zcchc6 is expressed in macrophages and impacts innate immune responses[J]. PLoS One, 2017, 12(6): e0179797.
[9]	Xin Z, Hua L, Yang YL, et al. A Pathway analysis based on genome－wide DNA methylation of Chinese patients with Graves′ orbitopathy[J]. Biomed Res Int, 2019, PMID: 9565794.
[10]	Wang X, Liu W, Rui Z, et al. Immunotherapy with a biologically active ICAM－1 mAb and an siRNA targeting TSHR in a BALB/c mouse model of Graves′ disease[J]. Endokrynol Pol, 2021, 72(6): 592－600.
[11]	Brooks J, Watson A, Korcsmaros T. Omics approaches to identify potential biomarkers of inflammatory diseases in the focal adhesion complex[J]. Genomics Proteomics Bioinformatics, 2017, 15(2): 101－109.
[12]	Shi TT, Hua L, Xin Z, et al. Identifying and validating genes with DNA methylation data in the context of biological network for Chinese patients with Graves′ orbitopathy[J]. Int J Endocrinol, 2019, PMID: 6212681.
[13]	Matsui M, Corey DR. Non－coding RNAs as drug targets[J]. Nat Rev Drug Discov, 2017, 16(3): 167－179.
[14]	Cech TR, Steitz JA. The noncoding RNA revolution－trashing old rules to forge new ones[J]. Cell, 2014, 157(1): 77－94.
[15]	Li K, Du Y, Jiang BL, et al. Increased microRNA－155 and decreased microRNA－146a may promote ocular inflammation and proliferation in Graves′ ophthalmopathy[J]. Med Sci Monit, 2014, 20: 639－643.
[16]	Woeller CF, Roztocil E, Hammond C, et al. TSHR Signaling stimulates proliferation through PI3K/Akt and induction of miR－146a and miR－155 in thyroid eye disease orbital fibroblasts[J]. Invest Ophthalmol Vis Sci, 2019, 60(13): 4336－4345.
[17]	Wang N, Chen FE, Long ZW. Mechanism of MicroRNA－146a/Notch2 signaling regulating IL－6 in Graves ophthalmopathy[J]. Cell Physiol Biochem, 2017, 41(4): 1285－1297.
[18]	Jang SY, Chae MK, Lee JH, et al. Role of miR－146a in the regulation of inflammation in an in vitro model of Graves′ orbitopathy[J]. Invest Ophthalmol Vis Sci, 2016, 57(10): 4027－4034.
[19]	Jang SY, Park SJ, Chae MK, et al. Role of microRNA－146a in regulation of fibrosis in orbital fibroblasts from patients with Graves′ orbitopathy[J]. Br J Ophthalmol, 2018, 102(3): 407－414.
[20]	Liu W, Ma C, Li HY, et al. MicroRNA－146a downregulates the production of hyaluronic acid and collagen Ⅰ in Graves′ ophthalmopathy orbital fibroblasts[J]. Exp Ther Med, 2020, 20(5): 38.
[21]	Wei H, Guan M, Qin Y, et al. Circulating levels of miR－146a and IL－17 are significantly correlated with the clinical activity of Graves′ ophthalmopathy[J]. Endocr J, 2014, 61(11): 1087－1092.
[22]	Ortega－Campos SM, García－Heredia JM.The multitasker protein: a look at the multiple capabilities of NUMB[J]. Cells, 2023, 12(2): 333.
[23]	Hu ZJ, He JF, Li KJ, et al. Decreased microRNA－146a in CD4⁺T cells promote ocular inflammation in thyroid－associated ophthalmopathy by targeting NUMB[J]. Eur Rev Med Pharmacol Sci, 2017, 21(8): 1803－1809.
[24]	杨文娟，班胜刚，何剑峰. 甲状腺相关眼病患者外周血单个核细胞中微小RNA－146a的异常表达及意义[J]. 眼科新进展，2012，32(5)：414－417.
[25]	Martínez－Hernández R, Sampedro－Núňez M, Serrano－Somavilla A, et al. A MicroRNA signature for evaluation of risk and severity of autoimmune thyroid diseases[J]. J Clin Endocrinol Metab, 2018, 103(3): 1139－1150.
[26]	Lee JY, Yun M, Paik JS, et al. PDGF－BB enhances the proliferation of cells in human orbital fibroblasts by suppressing PDCD4 expression via up－regulation of microRNA－21[J]. Invest Ophthalmol Vis Sci, 2016, 57(3): 908－913.
[27]	Tong BD, Xiao MY, Zeng JX, et al. MiRNA－21 promotes fibrosis in orbital fibroblasts from thyroid－associated ophthalmo－pathy[J]. Mol Vis, 2015, 21: 324－334.
[28]	Hammond CL, Roztocil E, Gonzalez MO, et al. MicroRNA－130a is elevated in thyroid eye disease and increases lipid accumulation in fibroblasts through the suppression of AMPK[J]. Invest Ophthalmol Vis Sci, 2021, 62(1): 29.
[29]	Wu Y, Guan S, Ge Y, et al. Cigarette smoke promotes chronic obstructive pulmonary disease (COPD) through the miR－130a/Wnt1 axis[J]. Toxicol In Vitro, 2020, 65: 104770.
[30]	Lin Q, Gao Z, Alarcon RM, et al. A role of miR－27 in the regulation of adipogenesis[J]. FEBS J, 2009, 276(8): 2348－2358.
[31]	Jang SY, Chae MK, Lee JH, et al. MicroRNA－27 inhibits adipogenic differentiation in orbital fibroblasts from patients with Graves′ orbitopathy[J]. PLoS One, 2019, 14(8): e0221077.
[32]	Shi XE, Li YF, Jia L, et al. MicroRNA－199a－5p affects porcine preadipocyte proliferation and differentiation[J]. Int J Mol Sci, 2014, 15(5): 8526－8538.
[33]	Gao Y, Cao Y, Cui X, et al. miR－199a－3p regulates brown adipocyte differentiation through mTOR signaling pathway[J]. Mol Cell Endocrinol, 2018, 476: 155－164.
[34]	Craps J, Joris V, Baldeschi L, et al. miR－199a downregulation as a driver of the NOX4/HIF－1α/VEGF－A pathway in thyroid and orbital adipose tissues from Graves′ patients[J]. Int J Mol Sci, 2021, 23(1): 153.
[35]	Lanzolla G, Marinò M, Marcocci C．Selenium in the treatment of Graves′ hyperthyroidism and eye disease[J]. Front Endocrinol (Lausanne), 2020, 11: 608428.
[36]	Thiel J, Alter C, Luppus S, et al. MicroRNA－183 and microRNA－96 are associated with autoimmune responses by regulating T cell activation[J]. J Autoimmun, 2019, 96: 94－103.
[37]	Fuentes－Calvo I, Blázquez－Medela AM, Eleno N, et al. H－Ras isoform modulates extracellular matrix synthesis, proliferation, and migration in fibroblasts[J]. Am J Physiol Cell Physiol, 2012, 302(4): C686－C697.
[38]	Tan J, Tong BD, Wu YJ, et al. MicroRNA－29 mediates TGFβ1－induced extracellular matrix synthesis by targeting wnt/β－catenin pathway in human orbital fibroblasts[J]. Int J Clin Exp Pathol, 2014, 7(11): 7571－7577.
[39]	Tang W, Lv Q, Huang X, et al. MiR－143 Targets IGF－1R to suppress autoimmunity in thyroid－associated ophthalmopathy[J]. J Inflamm Res, 2022, 15: 1543－1554.
[40]	Khong JJ, McNab AA, Ebeling PR, et al. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms[J]. Br J Ophthalmol, 2016, 100(1): 142－150.
[41]	Zhang L, Masetti G, Colucci G, et al. Combining micro－RNA and protein sequencing to detect robust biomarkers for Graves′ disease and orbitopathy[J]. Sci Rep, 2018, 8(1): 8386.
[42]	Wu L, Li L, Liang Y, et al. Identification of differentially expressed long non－coding RNAs and mRNAs in orbital adipose/connective tissue of thyroid－associated ophthalmopathy[J]. Genomics, 2021, 113(2): 440－449.
[43]	Wang N, Hou SY, Qi X, et al. LncRNA LPAL2/miR－1287－5p/EGFR axis modulates TED－derived orbital fibroblast activation through cell adhesion factors[J]. J Clin Endocrinol Metab, 2021, 106(8): e2866－e2886.
[44]	Wu L, Zhou R, Diao J, et al. Differentially expressed circular RNAs in orbital adipose/connective tissue from patients with thyroid－associated ophthalmopathy[J]. Exp Eye Res, 2020, 196: 108036.
[45]	Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language？[J] Cell, 2011, 146(3): 353－358.
[46]	Yue Z, Mou P, Chen S, et al. A novel competing endogenous RNA network associated with the pathogenesis of Graves′ ophthalmopathy[J]. Front Genet, 2021, 12: 795546.
[47]	Yue Z, Tong F, Zeng C, et al. Identification of tRNA－related fragments and their potential regulatory effects in thyroid－associated ophthalmopathy[J]. Front Genet, 2022, 13: 878405.
[48]	Zhang Y, Sun Z, Jia J, et al. Overview of histone modification[J]. Adv Exp Med Biol, 2021, 1283: 1－16.
[49]	Matheis N, Lantz M, Grus FH, et al. Proteomics of orbital tissue in thyroid－associated orbitopathy[J]. J Clin Endocrinol Metab, 2015, 100(12): E1523－ E1530.
[50]	Ekronarongchai S, Palaga T, Saonanon P, et al. Histone deacetylase 4 controls extracellular matrix production in orbital fibroblasts from Graves′ ophthalmopathy patients[J]. Thyroid, 2021, 31(10): 1566－1576.

影响途径	表观遗传调控
眼眶脂肪代谢	miRNA－130、miRNA－27及miRNA－199a
	长链非编码RNA
	环状RNA_10135
	转运核糖核酸衍生片段5－葡萄糖胞嘧啶－磷酸－鸟嘌呤
	组蛋白H4
眼眶成纤维细胞增值	miRNA－155、miRNA－146a 、miRNA－21及miRNA－29
	长链非编码RNA－脂蛋白相关磷脂酶A2
	环状RNA_14940
	转运核糖核酸衍生片段5－葡萄糖胞嘧啶－磷酸－鸟嘌呤
	组蛋白去乙酰化酶4
自身免疫反应	miRNA－183和miRNA－96
	环状RNA_14936
	竞争内源性RNA
透明质酸沉积	miRNA－146a和miRNA－143
待研究	19_15038、人miRNA－182－5p、miRNA－27a－3p、miRNA－22－3p及miRNA－6748－3p

影响途径	表观遗传调控
眼眶脂肪代谢	miRNA－130、miRNA－27及miRNA－199a
	长链非编码RNA
	环状RNA_10135
	转运核糖核酸衍生片段5－葡萄糖胞嘧啶－磷酸－鸟嘌呤
	组蛋白H4
眼眶成纤维细胞增值	miRNA－155、miRNA－146a 、miRNA－21及miRNA－29
	长链非编码RNA－脂蛋白相关磷脂酶A2
	环状RNA_14940
	转运核糖核酸衍生片段5－葡萄糖胞嘧啶－磷酸－鸟嘌呤
	组蛋白去乙酰化酶4
自身免疫反应	miRNA－183和miRNA－96
	环状RNA_14936
	竞争内源性RNA
透明质酸沉积	miRNA－146a和miRNA－143
待研究	19_15038、人miRNA－182－5p、miRNA－27a－3p、miRNA－22－3p及miRNA－6748－3p

Please choose a citation manager

Content to export